Page last updated: 2024-10-15

fce 22250

Description

FCE 22250: active against Mycobacterium [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135889905
MeSH IDM0123230

Synonyms (4)

Synonym
fce 22250
84475-07-0
[(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21e,26e)-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-26-[[(2e)-2-(piperidin-1-ylmethylidene)hydrazinyl]methylidene]-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(
[(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21e)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-26-[(z)-[(e)-piperidin-1-ylmethylidenehydrazinylidene]methyl]-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,

Bioavailability

ExcerptReference
" The ig absolute bioavailability ranged from 69-84%."( [Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats].
Li, D; Liu, L; Sun, SL; Wang, ZY, 1991
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]